Skip to content
Clinical Trials – home
Verifiedinfo

Institut fuer Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH

Germany Albert-Einstein-Allee 23, Eselsberg, 89081 Ulm, Germany

  • 213 trials recruiting
  • Colitis ulcerative · Crohn's disease · Breast cancer
  • Adults and children

About Specializations

Institut fuer Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH in Ulm, Germany specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Breast cancer, Chronic lymphocytic leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Diseases

At Institut fuer Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH, clinical research is centered on immune system diseases, with a strong focus on Paroxysmal Nocturnal Hemoglobinuria. The studies are designed to better understand this rare condition and to assess new treatment options that may improve long-term disease control and patient well-being.

  • Research on Paroxysmal Nocturnal Hemoglobinuria and related immune-mediated blood disorders
  • Evaluation of the safety and tolerability of new therapies for long-term use
  • Clinical work aimed at improving treatment effectiveness for patients with chronic immune system conditions

With 8 trials and 96 investigators involved, the site in Ulm contributes to advancing care for rare hematologic and immunologic diseases through focused clinical evaluation.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Albert-Einstein-Allee 23, Eselsberg89081 UlmGermany
Recruiting now
213 trials
Conditions studied
203
Partner status
Verified

More sites in UlmGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

475 clinical trials

Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:USNOFLAST
  • Sponsor:Zydus Therapeutics Inc.
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).